Physician Assistant Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Laura Martin

Physician Assistant, Medical Homewood, AL Physician Assistant

NPI 1831489707 CMS profile 10476759

3485 Independence Dr, Homewood, AL 35209

Open in the dashboard

General payments

$4,001

172 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Laura Martin of Homewood, AL is reported in the CMS Open Payments database as having received $4,001 across 172 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $693 33
2023 General $1,416 65
2022 General $768 42
2021 General $1,124 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laura Martin
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Laura Martin were reported at $0. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Laura Martin Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,124 $156 $41–$563 $132
2022 $768 $185 $55–$649 $149
2023 $1,416 $199 $58–$717 $160
2024 $693 $206 $62–$740 $164
2025 $0 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Pfizer Inc. $615 36 payments
  2. Janssen Biotech, Inc. $532 23 payments
  3. Janssen Scientific Affairs, LLC $500 1 payment
  4. Merck Sharp & Dohme Corporation $377 20 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $273 14 payments
  6. Eisai Inc. $203 12 payments
  7. Dendreon Pharmaceuticals LLC $169 5 payments
  8. Medtronic, Inc. $161 2 payments
  9. E.R. Squibb & Sons, L.L.C. $152 10 payments
  10. AstraZeneca Pharmaceuticals LP $143 9 payments
  11. Other $876 40 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $3,239 168 payments
  2. Consulting Fee $500 1 payment
  3. Education $261 3 payments
Products named General payments · program years 2021–2024
  1. ERLEADA $1,014 23 payments
  2. XTANDI $600 35 payments
  3. KEYTRUDA $377 20 payments
  4. ORGOVYX $341 17 payments
  5. TALZENNA $282 17 payments
  6. INLYTA $275 19 payments
  7. Nubeqa $238 12 payments
  8. Lenvima $203 12 payments
  9. WELIREG $200 11 payments
  10. Xofigo $200 11 payments
  11. Other $1,757 87 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

405

Median for Physician Assistant: 241

Drug cost

$978,083

Median for Physician Assistant: $4,110

Branded share of claims

33.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtandi Enzalutamide Brand 17 $237,397
Nubeqa Darolutamide Brand 20 $216,369
Orgovyx Relugolix Brand 62 $181,207
Erleada Apalutamide Brand 11 $159,592
Lynparza Olaparib Brand 13 $150,885
Abiraterone Acetate Generic 37 $25,003
Myrbetriq Mirabegron Brand 11 $5,825
Tamsulosin Hcl Generic 65 $617
Prednisone Generic 61 $460
Alendronate Sodium Generic 62 $444

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 62 billing codes

Paid by Medicare

$379,893

Of which drugs: $332,093

Medicare patients

314

Average age 75

Services billed

15,273

31 women, 283 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 75%
Arthritis 49%
Diabetes 38%
Ischemic heart disease 36%
Chronic kidney disease 33%
Atrial fibrillation 22%
Depression 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 36 4,022 $75,371
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 67 220 $28,978

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PROVENGE
  • Dendreon Pharmaceuticals LLC $169
$169 — —
ORGOVYX
  • Sumitomo Pharma America, Inc. $73
  • PFIZER INC. $18
$91 62 —
XTANDI
  • PFIZER INC. $46
$46 17 —
TALZENNA
  • PFIZER INC. $46
$46 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $39
$39 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

172 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record